XKRX
950130
Market cap199mUSD
Aug 14, Last price
9,060.00KRW
Name
Access Bio Inc
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.30%
Rev. gr., 5y
21.17%
Revenues
112.46b
-67.74%
Net income
-348m
L-89.05%
CFO
19.90b
P
Dividend
Dec 28, 2022871 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Access Bio Inc., a U.S.-based biotechnology firm, specializes in the research, development, and manufacturing of advanced in vitro rapid diagnostic tests, biosensors, and molecular diagnostic solutions. These offerings are designed primarily for the prompt identification and prevention of infectious diseases. The company's core technological expertise spans immunochemical, biochemical, and molecular in vitro diagnostics. Among its diverse product range are rapid diagnostic tests like CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM. Their biosensor line features the CareStart G6PD Biosensor, while their molecular diagnostics portfolio includes CareStart HPV and CareStart CAH.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||